Literature DB >> 19430728

Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.

Antoine Hollebecque1, Antoine Adenis, Sophie Taieb, Claudia Lebedinsky, Nicolas Penel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19430728     DOI： 10.1007/s10637-009-9262-4

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  6 in total

1.  Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

Authors:  A Le Cesne; J Y Blay; I Judson; A Van Oosterom; J Verweij; J Radford; P Lorigan; S Rodenhuis; I Ray-Coquard; S Bonvalot; F Collin; J Jimeno; E Di Paola; M Van Glabbeke; O S Nielsen
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

2.  Measuring response in solid tumors: unidimensional versus bidimensional measurement.

Authors:  K James; E Eisenhauer; M Christian; M Terenziani; D Vena; A Muldal; P Therasse
Journal:  J Natl Cancer Inst       Date:  1999-03-17       Impact factor: 13.506

Review 3.  ET-743: a novel agent with activity in soft tissue sarcomas.

Authors:  Jérôme Fayette; Isabelle Ray Coquard; Laurent Alberti; Dominique Ranchère; Helen Boyle; Jean-Yves Blay
Journal:  Oncologist       Date:  2005 Nov-Dec

4.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Authors:  Haesun Choi; Chuslip Charnsangavej; Silvana C Faria; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Robert S Benjamin
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

Review 5.  Other endpoints in screening studies for soft tissue sarcomas.

Authors:  Jaap Verweij
Journal:  Oncologist       Date:  2008

6.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Authors:  Federica Grosso; Robin L Jones; George D Demetri; Ian R Judson; Jean-Yves Blay; Axel Le Cesne; Roberta Sanfilippo; Paola Casieri; Paola Collini; Palma Dileo; Carlo Spreafico; Silvia Stacchiotti; Elena Tamborini; Juan Carlos Tercero; Josè Jimeno; Maurizio D'Incalci; Alessandro Gronchi; Jonathan A Fletcher; Silvana Pilotti; Paolo G Casali
Journal:  Lancet Oncol       Date:  2007-07       Impact factor: 41.316
  6 in total
  3 in total

Review 1.  Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin.

Authors:  Frédéric Amant; Domenica Lorusso; Alexander Mustea; Florence Duffaud; Patricia Pautier
Journal:  Sarcoma       Date:  2015-05-18

Review 2.  Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.

Authors:  M D'Incalci; N Badri; C M Galmarini; P Allavena
Journal:  Br J Cancer       Date:  2014-04-22       Impact factor: 7.640

3.  Trabectedin in Advanced High-Grade Uterine Leiomyosarcoma: A Case Report Illustrating the Value of (18)FDG-PET-CT in Assessing Treatment Response.

Authors:  M J Payne; R E Macpherson; K M Bradley; A B Hassan
Journal:  Case Rep Oncol       Date:  2014-02-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.